PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the... Read more

Danaher Announces Investment Partnership in Innovaccer Inc.

Danaher Announces Investment Partnership in Innovaccer Inc. Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions. Investment aligns with Danaher’s mission to accelerate the transition to precision medicine with AI-enabled diagnostics. WASHINGTON, Jan. 9, 2025 /PRNewswire/ — Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (NYSE:... Read more

Danaher Schedules Fourth Quarter 2024 Earnings Conference Call

WASHINGTON, Jan. 2, 2025 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.... Read more

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the world. Laboratories can now perform a wider range of tests on a single solution, simplifying laboratory logistics and helping to optimise the use of resources. Basel, 13 December... Read more

PacBio Announces Third Quarter 2024 Financial Results

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million compared with $55.7 million in the prior-year period. Instrument revenue of $16.8 million compared with $34.7 million in the prior-year period. Instrument revenue in the... Read more